This study aims to examine the efficacy of minocycline augmentation in a sample of moderately
ill outpatients with early-course schizophrenia on their chlorpromazine-equivalent doses of
second-generation antipsychotic medications. The investigators hypothesize that as compared
to placebo a 2-month treatment with minocycline in 120 volunteers with early-course
schizophrenia will result in a more significant improvement in psychopathology (primary
outcome) and cognitive symptoms (secondary outcome). In addition, cytokine plasma levels will
be used as another secondary outcome measure to see if treatment-induced changes in total
PANSS score are associated with changes in cytokine levels.
Phase:
N/A
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston